Industry Trends

Clinical Research
Off-shoring: A Country Attractiveness Index for Clinical Trials

By Mark P. Mathieu
For many years, pharmaceutical companies have been off-shoring manufacturing operations to lower-cost countries. Healthy margins and strong risk aversion have afforded pharmaceutical companies the luxury of staying close to home, for all but manufacturing activities. As financial pressures increase, pharmaceutical executives are finding that going offshore is not only less risky than it once was, but also too attractive to ignore.  Read More



Implementing Core Clinical Trial Technologies



By Bill Byrom

February 16, 2010 | Expert Commentary | In the clinical space today, more technology solutions are being used, and investigational sites often employ multiple solutions within a single study to perform their responsibilities. Solutions include clinical trials management systems (CTMS), electronic data capture (EDC) systems, electronic patient reported outcomes (ePRO) solutions, randomization and trial supply management (RTSM) solutions (typically deployed using IVR/IWR technology), medical imaging technologies, central ECG management and reporting solutions, adverse event and safety systems to name but a few.

Common to every clinical trial are the requirements to project manage and track the study; collect and clean CRF data recorded by the investigator; and manage the logistics of the study including the medication supply chain and the randomization process.

Many biopharmaceutical companies have invested significantly in these technologies and have adapted their processes and procedures to benefit from their use. Most large and mid-sized companies performing a number of clinical trials per year have purchased and licensed a commercial CTMS application. Some smaller organizations manage the same meta data and processes using spreadsheets and databases and while this can be successful for single studies, it is challenging when managing data across a portfolio of trials.

Some biopharmaceutical companies have determined that all phase 2 and 3 trials should employ EDC, and have geared up data management and monitoring resources to adapt to and apply the new electronic processes. In addition to reducing data management costs, EDC is associated with improving data quality, in particular speeding the data cleaning process, and has been reported to result in lower monitoring costs. Furthermore, the benefits in simplifying logistics and saving medication when using RTSM systems have been realized by many biopharmaceutical companies. Consequently, like EDC adoption, some sponsors choose to employ RTSM by default in all phase 2-3 studies.

Other clinical trial technologies, with the exception of safety systems, are used by individual trials when required and so we might consider the combination of CTMS, EDC and RTSM as foundational and required by every clinical trial, from which additional technologies may be required on a per-study basis.

Integration of Core Clinical Trial Technology Solutions
The challenge now becomes how CTMS, EDC and RTSM can be used in combination optimally so that users are not faced with duplication of data and activities, and workflows are not burdened with unnecessary keying of data between systems. Additionally, how can other technologies be hooked into these systems when they are needed by a study? 

Although each has unique areas of focus and application, there is overlap between the data and functionality contained within CTMS, EDC and RTSM solutions. This overlap can lead to increased burden in their application. For example, one of the key functions of a CTMS is to provide up-to-date information on study progress including patient recruitment, data management and source data verification (SDV). Senior management rely upon these data being accurately recorded in the CTMS, and as a consequence CRAs are often required to re-key data into the CTMS based upon the information contained within RTSM and EDC reports.

In addition, site users may receive dispensing information from an RTSM system and be required to enter it into the eCRF within the EDC application. Users may make mistakes in entering duplicate information leading to the requirement to reconcile data between databases, or may simply not perform the activity as it appears redundant to them although valuable to another user of the system. Figure 2 depicts the typical touch points between CTMS, EDC and RTSM systems.

Integrating the data between these systems has enormous benefits to the different user types involved in the operation of a clinical trial. Ensuring the CTMS contains accurate study progress data leverages the use of that system as the key management information system within the Sponsor. Key study progress data, if up to date, can also trigger timely site payments.

Providing integration between EDC and RTSM makes working with both technologies more efficient for study site users and monitors in eliminating duplication of activities, data and associated reconciliation, and in ensuring that the optimal value is obtained from each technology investment. Integrating site address and user details contained in a CTMS with the other technology solutions that require that data removes the needs for CRAs and study managers to create and maintain accurate duplicate lists of this information.

Simple data integration brings significant benefits to the users of these core technologies and leverages the value of each

Bill Byrom is Senior Director of Product Strategy, Perceptive Informatics, Nottingham, UK. 

Click here to log in.

1 Comments

  • Avatar

    Why should a sponsor look beyond ePRO?
    It is a known fact that it take huge amount of capital, usually in billions of dollars to conduct and finally launch a dug into the market. It is also known that there are several studies that are either terminated or stopped half way due to several reasons technical and non-technical associated with it resulting in wastage of time and money both. Patient related data capture during a clinical trial plays an important role in the making of a drug. Through out the different phases of clinical trials information from patients are taken for efficacy, BA, BE measurements and make a considerable part of the trials or study. A lot of sponsors have been using ePRO to collect patient reported outcome, still makes only 30-40 % of studies being conducted using EDC and further less using ePRO.
    It is time that sponsors look at more cost effective ways to gather PRO from subjects under trials and keep abreast with the pace of developing technologies. The next big wave in capturing PRO for clinical trials is the use of mobile phones and I am sure there are many a company that are working on it. Mobile phones are going to be the next computers that would enable users to manage all their communication and information transfer over mobile phones.
    What can a sponsor look at from a mobile phone based PRO?
    Well there are quite a few things for a Sponsor or for that matter a CRO to be looking at, when it comes to mobile based PRO system.
    Faster
    Compliant
    Cost effective
    Patient safety
    Logistically simpler
    Less erroneous data
    Data integrity and security
    New and improved features
    A information management system
    Check out more on www.padisys.com. For any queries or information kindly call up
    +18184531805 for US and +91 9948220071 for India.

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now 

More Podcasts

Job Openings

Firmenich
PhD COMPUTATIONAL SYSTEMS SCIENTIST
To review full job description please go to www.Firmenich.com and search for Computational Biologist. All qualified candidates send updated resume to ppapiccio@agile1.com.
read more
abbott labs
Abbott Labs, Health Informatics Program ManagerQualified candidates may apply by posting their resume to www.abbott.com/careers. Reference number: 110844BR.
read more




For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .